Detalhe da pesquisa
1.
Wnt-ß-catenin activation epigenetically reprograms Treg cells in inflammatory bowel disease and dysplastic progression.
Nat Immunol
; 22(4): 471-484, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33664518
2.
Germline genetic contribution to the immune landscape of cancer.
Immunity
; 54(2): 367-386.e8, 2021 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33567262
3.
A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma.
Invest New Drugs
; 42(2): 179-184, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38372949
4.
The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy.
Curr Oncol Rep
; 25(3): 189-199, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36705879
5.
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Lancet Oncol
; 22(7): 946-958, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34143969
6.
The Tumor Microenvironment of Bladder Cancer.
Adv Exp Med Biol
; 1296: 275-290, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-34185299
7.
Mechanistic and pharmacologic insights on immune checkpoint inhibitors.
Pharmacol Res
; 120: 1-9, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28323141
8.
Do clinicians know which of their patients have central venous catheters?: a multicenter observational study.
Ann Intern Med
; 161(8): 562-7, 2014 Oct 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-25329204
9.
A phase I trial of enzalutamide plus selective glucocorticoid receptor modulator relacorilant in patients with metastatic castration resistant prostate cancer.
Clin Cancer Res
; 2024 Mar 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38536082
10.
Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model.
Front Immunol
; 15: 1358019, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38515743
11.
Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy.
Cell Rep
; 43(5): 114141, 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38656869
12.
Bladder-Preserving Trimodality Therapy With Capecitabine.
Clin Genitourin Cancer
; 22(2): 476-482.e1, 2024 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38228414
13.
Melanoma and microbiota: Current understanding and future directions.
Cancer Cell
; 42(1): 16-34, 2024 01 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38157864
14.
Mathematical model predicts tumor control patterns induced by fast and slow cytotoxic T lymphocyte killing mechanisms.
Sci Rep
; 13(1): 22541, 2023 12 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38110479
15.
Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study.
Clin Cancer Res
; 29(1): 110-121, 2023 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36282874
16.
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma.
Eur Urol Oncol
; 2023 Dec 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38105142
17.
A global method for fast simulations of molecular dynamics in multiscale agent-based models of biological tissues.
iScience
; 25(6): 104387, 2022 Jun 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35637730
18.
Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas.
Clin Cancer Res
; 28(4): 677-688, 2022 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34716197
19.
Hallmarks of Resistance to Immune-Checkpoint Inhibitors.
Cancer Immunol Res
; 10(4): 372-383, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35362046
20.
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial.
Clin Cancer Res
; 28(10): 2020-2029, 2022 05 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35165101